骨肉瘤中C-kit受体和血小板衍生生长因子受体-α的表达及意义  

Expression of C-kit receptor and platelet-derived growth factor receptor-α in osteosarcoma and their significance

作　　者：李晓琴[1] 王勇平[2] 杨荣[1] 刘芳[1] 罗雁[1] 康雅琼[1] 何欣[1] 尚立娜[1] 宋丽娟[1] 

机构地区：[1]甘肃省肿瘤医院病理科,兰州730050 [2]兰州大学第一医院骨科,兰州730000

出　　处：《临床与实验病理学杂志》2013年第8期868-870,875,共4页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的探讨C-kit受体(CD117)和血小板衍生生长因子受体-α(platelet-derived growth factor receptor-α,PDGFR-α)在骨肉瘤发病中的作用及其与骨肉瘤临床病理分型及预后的关系。方法采用免疫组化EnVision两步法检测60例骨肉瘤和10例骨瘤(对照组)中CD117和PDGFR-α的表达,分析二者的表达与骨肉瘤病理分型及临床预后的关系。结果骨肉瘤中CD117阳性率为66.7%(40/60),显著高于对照组(P<0.05);PDGFR-α阳性率为61.7%(37/60),显著高于对照组(P<0.05)。骨肉瘤中CD117和PDGFR-α表达无相关性(P>0.05)。CD117和PDGFR-α表达与病理分型无显著关系,与临床分期及预后密切相关。结论骨肉瘤中CD117及PDGFR-α的表达与其生物学行为密切相关,对评价患者的预后及指导临床治疗具有一定的参考价值。Purpose To investigate the expression of C-kit receptor （CD117） and platelet-derived growth factor receptor-α （PDGFR-α） in osteosarcoma and their relationships with pathological type and prognostic value. Methods CD117 and PDGFR-α were detected by immunohistochemistry （EnVision method）. The expression of CD117 and PDGFR-α was determined in 60 patients with osteosarcoma by immunohistochemistry. Their relationship with prognosis was statistically analyzed. Results The expression rate of CDll7 in osteosarcoma was 66. 7% （40/60）, which was significantly higher than that in the control group （P 〈 0. 05 ）. The expression rate of PDGFR-α in osteosarcoma was 61.7% （37/60）, which was significantly higher than that in the control group （P 〈0.05 ）. The expression in the osteosarcoma had no significant correlation between the CD117 and the PDGFR-α （P 〉 0.05 ）. The expression of CD117 and PDGFR-α had no relationship with the pathological types of the osteosarcoma, but dramatically related to the clinical stages. Conclusion The expression of CD117 and PDGFR-α is related to the biological behavior and pathological type of osteosarcoma in osteosarcoma, and it is valuable in judging the prognosis and therapy for osteosarcoma.

关 键 词：骨肉瘤 C-KIT受体 血小板衍生生长因子受体-α 

分 类 号：R738.1[医药卫生—肿瘤]